ArticleNature machine intelligence2026
Molecular deep learning at the edge of chemical space.
Article in Nature machine intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- TechBio 3.0 closes the drug discovery loop with multimodal AI and generative chemistry.npj drug discovery · 2026Review
- Improving Generalizability in Whole-Cell Antibiotic Discovery Through Active Learning.bioRxiv : the preprint server for biology · 2026Article
- Combating Antibacterial Resistance: The Integrative Role of Artificial Intelligence in Bio-Based Product Development.Antibiotics (Basel, Switzerland) · 2026Review
- Molecular deep learning at the edge of chemical space.Nature machine intelligence · 2026Article
- Going beyond SMILES enumeration for data augmentation in generative drug discovery.Digital discovery · 2025Article
- Generative Deep Learning for de Novo Drug Design─A Chemical Space Odyssey.Journal of chemical information and modeling · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular machine learning models often fail to generalize beyond the chemical space of their training data, limiting their ability to reliably perform predictions on structurally novel bioactive molecules. Here, to advance the ability of machine learning to go beyond the 'edge' of their training chemical space, we introduce a joint modelling approach that combines molecular property prediction with molecular reconstruction. This approach allows the introduction of unfamiliarity, a reconstruction-based metric that enables the estimation of model generalizability. Via a systematic analysis spanning more than 30 bioactivity datasets, we demonstrate that unfamiliarity not only effectively identifies out-of-distribution molecules but also serves as a reliable predictor of classifier performance. Even when faced with the presence of strong distribution shifts on large-scale molecular libraries, unfamiliarity yields robust and meaningful molecular insights that go unnoticed by traditional methods. Finally, we experimentally validate unfamiliarity-based molecule screening in the wet lab for two clinically relevant kinases, discovering seven compounds with low micromolar potency and limited similarity to training molecules. This demonstrates that unfamiliarity can extend the reach of machine learning beyond the edge of the charted chemical space, advancing the discovery of diverse and structurally novel molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.